Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Deferred Revenue (2021 - 2025)

Ocular Therapeutix has reported Current Deferred Revenue over the past 8 years, most recently at $14.0 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $14.0 million for Q4 2025, down 0.91% from a year ago — trailing twelve months through Dec 2025 was $14.0 million (down 0.91% YoY), and the annual figure for FY2025 was $14.0 million, down 0.91%.
  • Current Deferred Revenue for Q4 2025 was $14.0 million at Ocular Therapeutix, roughly flat from $14.0 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for OCUL hit a ceiling of $14.3 million in Q1 2022 and a floor of $64000.0 in Q1 2025.
  • Median Current Deferred Revenue over the past 5 years was $1.2 million (2022), compared with a mean of $6.8 million.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 97.76% in 2023 and later soared 5440.39% in 2024.
  • Ocular Therapeutix's Current Deferred Revenue stood at $13.0 million in 2021, then tumbled by 95.57% to $576000.0 in 2022, then plummeted by 55.73% to $255000.0 in 2023, then soared by 5440.39% to $14.1 million in 2024, then fell by 0.91% to $14.0 million in 2025.
  • The last three reported values for Current Deferred Revenue were $14.0 million (Q4 2025), $14.0 million (Q3 2025), and $14.0 million (Q2 2025) per Business Quant data.